ライフサイエンスコーパス: suicide gene therapy

1 nic alternative modality for prostate cancer suicide gene therapy.

2 d molecular imaging agents targeting HSV1-tk suicide gene therapy.

3 They are self-immolative prodrugs for suicide gene therapy activation by the enzyme carboxypep

4 Cancer suicide gene therapy affords the prospect of using the m

5 tween the oncolytic adenovirus and/or double-suicide gene therapies and radiation therapy.

6 , this cytokine approach was combined with a suicide gene therapy and subcutaneous B16 melanomas were

7 sent the findings on improved techniques for suicide gene therapy and various oncolytic viral therapi

8 ndidate for anti-microbial drug development, suicide-gene therapy, and cell-specific mRNA labeling te

9 We designed a novel suicide gene therapy approach wherein the gene product (

10 In an effort to optimize this suicide gene therapy approach, we have determined the th

11 x virus type 1 (HSV-1) thymidine kinase (TK) suicide gene therapy as a potential antitumor treatment.

12 this attribute could be exploited in cancer suicide gene therapy by using a lentiviral (LV) vector e

13 ication-competent adenovirus-mediated double-suicide gene therapy can be combined safely with convent

14 hypothesis that the effectiveness of HSV-TK suicide gene therapy can be enhanced by coexpression of

15 deficiencies, chronic granulomatous disease, suicide gene therapy for graft-versus-host disease, vira

16 d HVP22 to enhance Etk/ganciclovir (Etk/GCV) suicide gene therapy for neuroblastomas by GCV cytotoxic

17 Clinical experience with suicide gene therapy for prostate cancer using first-gen

18 ductase enzyme (NTR) has been widely used in suicide gene therapy (GDEPT and ADEPT) applications as a

19 udied antiglioma gene therapy strategies are suicide gene therapy, genetic immunotherapy and oncolyti

20 utic potential of BVP22 and HVP22 in Etk/GCV suicide gene therapy in this tumor system is not due to

21 Suicide gene therapy is one approach being evaluated for

22 emonstrate that CID-regulated, caspase-based suicide gene therapy is safe and can inhibit the growth

23 One example of suicide gene therapy is the bacterial nitroreductase (NT

24 Suicide gene therapy may contribute to the treatment of

25 Adenovirus-mediated suicide gene therapy may hold promise in the treatment o

26 Suicide gene therapy of cancer is a method whereby cance

27 e cell-based, non-viral or viral vectors for suicide gene therapy of cancer make more informed decisi

28 B1954) have been used for stem cell mediated suicide gene therapy of cancer.

29 evelop a stem cell-based system for targeted suicide gene therapy of recurrent, metastatic, and unres

30 ible to utilize such nucleoside analogues in suicide gene therapy or protein therapy applications tha

31 Suicide gene therapies provide a unique ability to targe

32 or obstacle to the successful application of suicide gene therapy strategies that rely on in situ tra

33 in combination with the pro-drug CB1954 in a suicide gene therapy strategy.

34 We have designed a targeted systemic suicide gene therapy that combines the advantages of tum

35 evaluated the safety and efficacy of a novel suicide gene therapy that could potentially spare normal

36 fferences have been exploited in a potential suicide gene therapy treatment for solid tumors.

37 Suicide gene therapy using the cytosine deaminase (CD) g

38 with established liver metastases show that suicide gene therapy using TK- vaccinia virus as a vecto

39 Suicide gene therapy using vv with the CD/5-FC system le

40 Thus, telomerase-specific suicide gene therapy vectors expressing bacterial nitror

41 est the potential therapeutic efficacy of DT suicide gene therapy, we first developed a DT-resistant

42 Using HSVtk suicide gene therapy, we showed that macrophages can dis

43 In a mouse xenograft model of lung cancer, suicide gene therapy with LV-ARE-TK/GCV was effective co

44 Suicide gene therapy with the herpes simplex virus thymi